About
Developing antibody-drug conjugates for cancer
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Team (21)
Cariad Chester
Managing Partner, TCGX
Adcendo
team_member
Carolyn Ng
Partner, TPG Capital
Adcendo
team_member
Dominik Mumberg
Chief Scientific Officer
Adcendo
executive
Fang Z
Chief Financial Officer
Adcendo
executive
Iyona Rajkomar
Managing Partner, Dawn Biopharma
Adcendo
team_member
James Wang
VP, Head of Business Development
Adcendo
executive
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
480
By Phase
PHASE1/PHASE2: 1PHASE1: 1
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06797999Lead Sponsor
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
PHASE1/PHASE2Recruiting
270 participants
Started: Jun 5, 2025 · Completed: Feb 27, 2029
NCT06597721Lead Sponsor
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
PHASE1Recruiting
210 participants
Started: Nov 25, 2024 · Completed: Dec 31, 2026
Locations (1)
Headquarters
Frederiksberg, Denmark
Map
Loading map...